Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...

The NDDC launches a sickle cell awareness campaign in Delta, providing medical support, drugs, and education to patients and ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

Agios Pharmaceuticals said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but failed to show a statistically significant ...

Shares of Agios Pharmaceuticals sank after the company said a phase three trial of its mitapivat drug to treat Sickle Cell Disease missed some of its endpoints. The stock fell 34% to $30 after closing ...

Agios Pharma reports mixed Phase 3 results for its sickle cell drug, mitapivat, highlighting the complex drug development and ...

Investing.com -- Fulcrum Therapeutics (NASDAQ:FULC) stock surged 20% after competitor Agios Pharmaceuticals reported mixed results from its sickle cell disease (SCD) drug trial, potentially clearing a ...

Senator Katung defends Nigeria's new sickle cell bill, inspired by personal tragedy, to establish treatment centers and ...

Nigeria’s Minister of State for Health, Dr Adekunle Salako, has revealed that one of the herbal medicines developed in the ...

Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study ​of patients aged 16 and older, but failed to show a statistically ‌significant ...

Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a ...